People Mirian Janssen Patient cohorts and clinical trials in mitochondrial disease

Convert scientific advances into benefits

This research group collects clinical, biochemical and genetic information of patients in order to convert scientific advances into benefits for patients with mitochondrial disease.

read more

Convert scientific advances into benefits

The collection of clinical, biochemical and genetic information of patients with mitochondrial disease is extremely valuable, allowing assessment of disease transmission, severity and progression.

The “National inventory of patients with the m.3243A>G mutation” study, including both symptomatic and asymptomatic carriers of the m.3243A>G mutation (MELAS mutation) is a clinical study being run by doctors experienced in the care of patients with mitochondrial disease at the Radboudumc Nijmegen. This study started in 2010 and is still running.

Recently the ‘’National inventory of patient with a LHON mutation” started, including patients and their maternal relatives with a LHON mutation.

Research group leader

Mirian Janssen MD PhD
medical research specialist

+31 (0)24 361 88 19
contact

Aims

The aim of the cohort studies is to convert scientific advances into benefits for patients with mitochondrial disease. In some cases this will be through assisting the set-up of clinical trials (developing outcome measures for mitochondrial disease) or treatments such as exercise or specific drugs.

Team

Radboud Institute for Molecular Life Sciences

Our main aim is to achieve a greater understanding of the molecular mechanisms of disease. By integrating fundamental and clinical research, we obtain multifaceted knowledge of (patho)physiological processes. read more